This is a preview of subscription content, log in via an institution to check access.
Notes
2019 US dollars
Reference
Bensimon AG, et al. An Economic Evaluation of Pembrolizumab Versus Other Adjuvant Treatment Strategies for Resected High-Risk Stage III Melanoma in the USA. Clinical Drug Investigation : 16 May 2020. Available from: URL: https://doi.org/10.1007/s40261-020-00922-6
Rights and permissions
About this article
Cite this article
Adjuvant pembrolizumab cost effective for stage III melanoma. PharmacoEcon Outcomes News 854, 3 (2020). https://doi.org/10.1007/s40274-020-6833-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-6833-2